Century Therapeutics Inc. Common Stock (IPSC)
Stock · NASDAQ · Health Care
$1.38as of 10/16/2026
Price chart
Active signals
IPSC Signal Track Record
How signals performed across all stocks →What IPSC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -6.5% | 27% | October 6, 2026 |
| Bollinger Band Breakdown | 22 | +2.3% | 55% | October 6, 2026 |
| Bollinger Band Breakout | 22 | -6.3% | 36% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -16.6% | 25% | September 14, 2026 |
| Any 20-session window (baseline) | -4.4% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308,…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 78
- Website
- www.centurytx.com/
Fundamentals
- 1-day range
- $1.36$1.52
- Market cap
- $342.67M
- P/E (trailing)
- —
- P/E (forward)
- -3.33
- EPS (trailing)
- $-0.90
- Dividend yield
- —
- Beta
- 1.74
- Avg. volume
- 612.4K
How Century Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Century Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026Yahoo · 10/2/2026
- Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026Benzinga · 10/2/2026
- Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest BetSeekingAlpha · 9/30/2026
Insider Activity
Insider Actions →- Gregory Russotti · September 14, 2026 · Sale2.6K @ $1.93
- Douglas Carr · September 14, 2026 · Sale1.7K @ $1.93
- Brent Pfeiffenberger · September 11, 2026 · Tax Withholding13.8K @ $1.94
- Truitt Joseph · September 9, 2026 · Grant148.0K
- Gregory Russotti · September 8, 2026 · Sale534 @ $2.05
- Douglas Carr · September 8, 2026 · Sale254 @ $2.05
- Brent Pfeiffenberger · September 4, 2026 · Tax Withholding463 @ $2.11
- Brent Pfeiffenberger · August 14, 2026 · Tax Withholding31.2K @ $1.92
- Douglas Carr · August 3, 2026 · Sale275 @ $1.98
- Gregory Russotti · June 12, 2026 · Sale2.6K @ $2.23
- Douglas Carr · June 12, 2026 · Sale1.7K @ $2.23
- Chad Cowan · June 11, 2026 · Tax Withholding358 @ $2.24
- Brent Pfeiffenberger · June 11, 2026 · Tax Withholding13.8K @ $2.24
- Murphy Martin Patrick · June 11, 2026 · Grant74.0K
- Lee Han Myung · June 11, 2026 · Grant74.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 136.66M
- Total value held
- $306.92M
- Institutional holders
- 70
- Unknown17.75M
- Unknown17.75M
- Unknown12.17M
- Unknown9.49M
- Unknown8.70M
- Unknown8.70M
- Unknown8.70M
- Unknown5.96M
- Unknown5.69M
- Unknown5.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.